Last update 01 Nov 2024

KLK2 x CD3

Basic Info

Related Targets
KLK2CD3

Related

1
Drugs associated with KLK2 x CD3
JNJ-78278343
Target
CD3 x KLK2
Mechanism
CD3 stimulants [+1]
Active Org.
Janssen Research & Development LLC
Originator Org.
Janssen Research & Development LLC [+1]
Active Indication
Metastatic castration-resistant prostate cancer [+1]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
4
Clinical Trials associated with KLK2 x CD3
NCT06095089 / RecruitingPhase 1
A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer
NCT05818683 / RecruitingPhase 1
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer
100 Clinical Results associated with KLK2 x CD3
Login to view more data
100 Translational Medicine associated with KLK2 x CD3
Login to view more data
0 Patents (Medical) associated with KLK2 x CD3
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free